Biosimilars

Studies Reveal Positive Results for Infliximab Biosimilar

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

Rituximab Biosimilar Now Available in United States for Rheumatoid Arthritis

May 04, 2020

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Merck Announces US Launch of Trastuzumab Biosimilar

April 15, 2020

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

FDA Approves 420-mg Multi-Dose Vial of Trastuzumab Biosimilar

March 24, 2020

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

Pfizer Announces US Launch of 3 New Oncology Biosimilars

January 23, 2020

Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.

FDA Approves Amgen’s Infliximab-axxq

December 06, 2019

Biosimilar to Remicade

Pfizer Gains FDA Approval for Humira Biosimilar

November 18, 2019

Expected U.S. launch in 2023.

Biosimilars: Some Call for ‘Cautious Optimism’

October 01, 2019

Biosimilars may need more time to devleop in the market.

Biosimilars Need Access and Cost Examinations

September 27, 2019

Biologic medicines could lower spending by $153 billion by 2023.

Generics and Biosimilars Facing Formulary Difficulties

September 11, 2019

New changes are making it more difficult for generics and biosimilars to compete on formularies.

x